HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nestlé Weighing Acquisition Of The Bountiful Company

Executive Summary

Nestlé is in talks to acquire "all or part" of The Bountiful Company, owners of the Nature's Bounty brand and a leading player in the US supplements market. The Swiss firm revealed its interest in The Bountiful Company shortly after reporting double-digit growth at its Health Science business in Q1. 

You may also be interested in...



Aceto’s Biotron Labs Acquisition Latest Thrust In Wave Of VMS Sector Investment During Pandemic

Not only are larger firms acquiring smaller competitors or expanding portfolios by adding brands, private equity and venture capital groups accelerate buying into sector. The latest is New Mountain Capital-owned Aceto acquiring Biotron Laboratories and its Talus Mineral business.

Nestlé Not Interested In Wider Consumer Health Play, Will Stick To VMS And Nutrition

While Nestle has made a success of its push into the dietary supplements market, don't expect to see the company make a move into the wider consumer health space. The company's Health Science unit recorded double-digit growth in 2021, but will remain focused on its core categories.

Nestle Harvests Plant-Based Protein Firm Orgain As Latest US Nutrition Business Investment

Nestle Health Science has expanded its nutritional footprint steadily since 2017 but investing in Orgain, with option to fully acquire in 2024 brings its first business working exclusively with plant-based ingredients.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS151261

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel